JY
IMMX icon

Jeff Yass’s Immix Biopharma IMMX Stock Holding History

Jeff Yass’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$676K Buy
65,600
+39,600
+152% +$367K ﹤0.01% 9192
2026
Q1 		$237K Sell
26,000
-9,200
-26% -$67.6K ﹤0.01% 11371
2025
Q4 		$184K Buy
+35,200
New +$145K ﹤0.01% 10969

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's IMMX Position: Q2 2026 in Review

Jeff Yass reduced its Immix Biopharma (IMMX) stake by 92% in Q2 2026, selling an estimated $4.01M and leaving 38,731 shares worth $399K. The position accounts for ﹤0.01% of the portfolio, ranked #10416.

Jeff Yass first reported a position in IMMX in Q1 2023 and has held it in 9 quarters since. The position peaked at $4.29M in Q1 2026. 108 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Jeff Yass held 38,731 shares of Immix Biopharma worth $399K as of Q2 2026.
  • Jeff Yass sold 432,663 Immix Biopharma shares in Q2 2026, an estimated $4.01M.
  • Immix Biopharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10416 holding.
  • Jeff Yass first reported a position in Immix Biopharma in Q1 2023 and has held it in 9 quarters since.
  • Jeff Yass's Immix Biopharma position peaked at $4.29M in Q1 2026.
  • 108 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.